CTKB (Cytek Biosciences, Inc.) Stock Financials & Earnings

CTKBCytek Biosciences, Inc.

Mkt Cap$553M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Revenue (TTM)$201M

Net Income (TTM)-$67M

EPS (TTM)-$0.52

Free Cash Flow (TTM)-$9M

Gross Margin51.8%

Op. Margin-20.0%

Net Margin-33.0%

FCF Margin-4.4%

P/S Ratio (TTM)2.7x

P/E Ratio (TTM)—

YoY Rev Growth+0.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$37M	$21M	-$12M
Q2 23	$50M	$28M	-$9M
Q3 23	$48M	$27M	-$6M
Q4 23	$58M	$33M	-$137K
Q1 24	$45M	$23M	-$11M
Q2 24	$47M	$25M	-$9M
Q3 24	$52M	$29M	-$4M
Q4 24	$57M	$34M	$3M
Q1 25	$41M	$20M	-$15M
Q2 25	$46M	$24M	-$11M
Q3 25	$52M	$28M	-$9M
Q4 25	$62M	$33M	-$6M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$10M	$12M	$11M
Q2 23	$12M	$11M	$14M
Q3 23	$11M	$10M	$12M
Q4 23	$11M	$11M	$12M
Q1 24	$10M	$11M	$13M
Q2 24	$10M	$12M	$12M
Q3 24	$10M	$11M	$12M
Q4 24	$10M	$9M	$12M
Q1 25	$10M	$13M	$13M
Q2 25	$9M	$14M	$12M
Q3 25	$9M	$16M	$12M
Q4 25	$9M	$16M	$13M

Revenue Segments

Quarter	Product	Service
Q1 23	$31M	$6M
Q2 23	$40M	$9M

Revenue by Geography

Quarter	Asia Pacific	Emea	Other	United States
Q1 23	$6M	$10M	$996K	$20M
Q2 23	$7M	$9M	$2M	$31M
Q3 23	$7M	$13M	$2M	$27M
Q4 23	$12M	$21M	$2M	$24M
Q1 24	$6M	$15M	$2M	$21M
Q2 24	$9M	$14M	$1M	$22M
Q3 24	$9M	$17M	$979K	$24M
Q1 25	$9M	$12M	$2M	$19M
Q2 25	$8M	$12M	$2M	$24M
Q3 25	$11M	$12M	$2M	$27M
Q4 25	$13M	$20M	$4M	$26M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$129M	$170M	$299M
Q2 23	$132M	$167M	$299M
Q3 23	$164M	$124M	$288M
Q4 23	$167M	$95M	$262M
Q1 24	$169M	$101M	$270M
Q2 24	$178M	$99M	$277M
Q3 24	$162M	$116M	$278M
Q4 24	$99M	$179M	$278M
Q1 25	$95M	$170M	$266M
Q2 25	$75M	$187M	$262M
Q3 25	$93M	$168M	$262M
Q4 25	$91M	$171M	$262M

Shares Outstanding

Revenue Per Employee

Revenue / Employee